Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial by Jiang, Zefei, Prof, Li, Wei, Prof, Hu, Xichun, Prof, Zhang, Qingyuan, Prof, Sun, Tao, Prof, Cui, Shude, Prof, Wang, Shusen, Prof, Ouyang, Quchang, Prof, Yin, Yongmei, Prof, Geng, Cuizhi, Prof, Tong, Zhongsheng, Prof, Cheng, Ying, Prof, Pan, Yueyin, Prof, Sun, Yuping, MD, Wang, Hong, MD, Ouyang, Tao, Prof, Gu, Kangsheng, Prof, Feng, Jifeng, Prof, Wang, Xiaojia, Prof, Wang, Shubin, Prof, Liu, Tianshu, Prof, Gao, Jinghua, MD, Cristofanilli, Massimo, Prof, Ning, Zhiqiang, MD, Lu, Xianping, PhD

Get full text

Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibit... by Lu, Shun, Prof, Wu, Lin, Prof, Jian, Hong, MD, Chen, Ying, Prof, Wang, Qiming, MD, Fang, Jian, Prof, Wang, Ziping, MD, Hu, Yanping, Prof, Sun, Meili, MD, Han, Liang, MD, Miao, Liyun, Prof, Ding, Cuimin, MD, Cui, Jiuwei, Prof, Li, Baolan, Prof, Pan, Yueyin, Prof, Li, Xingya, MD, Ye, Feng, MD, Liu, Anwen, Prof, Wang, Ke, MD, Cang, Shundong, MD, Zhou, Hui, MD, Sun, Xing, MD, Ferry, David, MD, Lin, Yong, MD, Wang, Shuyan, MD, Zhang, Wen, MD, Zhang, Chengli, MD

Get full text

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, ra... by Xu, Jianming, Prof, Kato, Ken, MD, Raymond, Eric, Prof, Hubner, Richard A, BM BCh, Shu, Yongqian, Prof, Pan, Yueyin, Prof, Park, Sook Ryun, Prof, Ping, Lu, MD, Jiang, Yi, MD, Zhang, Jingdong, Prof, Wu, Xiaohong, MD, Yao, Yuanhu, MD, Shen, Lin, Prof, Kojima, Takashi, Prof, Gotovkin, Evgeny, MD, Ishihara, Ryu, MD, Wyrwicz, Lucjan, Prof, Van Cutsem, Eric, Prof, Jimenez-Fonseca, Paula, MD, Lin, Chen-Yuan, MD, Wang, Lei, MD, Shi, Jingwen, PhD, Li, Liyun, MD, Yoon, Harry H, Prof

Get full text

Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced br... by Zhang, Pin, Prof, Zhang, Qingyuan, Prof, Tong, Zhongsheng, Prof, Sun, Tao, Prof, Li, Wei, Prof, Ouyang, Quchang, Prof, Hu, Xichun, Prof, Cheng, Ying, Prof, Yan, Min, Prof, Pan, Yueyin, Prof, Teng, Yuee, Prof, Yan, Xi, Prof, Wang, Ying, Prof, Xie, Weimin, Prof, Zeng, Xiaohua, Prof, Wang, Xiaojia, Prof, Hu, Changlu, Prof, Geng, Cuizhi, Prof, Zhang, Hongwei, Prof, Li, Wenxin, Prof, Wu, Xinhong, Prof, Zhong, Jincai, Prof, Xu, Jingwei, Prof, Shi, Yanxia, PhD, Wei, Wenhua, PhD, Bayaxi, Nayima, PhD, Zhu, Xiaoyu, PhD, Xu, Binghe, Prof

Get full text

Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised,... by Huang, Jing, Prof, Xu, Jianming, Prof, Chen, Yun, MD, Zhuang, Wu, MD, Zhang, Yiping, Prof, Chen, Zhendong, Prof, Chen, Jia, Prof, Zhang, Helong, Prof, Niu, Zuoxing, Prof, Fan, Qingxia, Prof, Lin, Lizhu, Prof, Gu, Kangsheng, Prof, Liu, Ying, MD, Ba, Yi, Prof, Miao, Zhanhui, MD, Jiang, Xiaodong, MD, Zeng, Ming, Prof, Chen, Jianhua, Prof, Fu, Zhichao, MD, Gan, Lu, MD, Wang, Jun, Prof, Zhan, Xianbao, Prof, Liu, Tianshu, Prof, Li, Zhiping, Prof, Shen, Lin, Prof, Shu, Yongqian, Prof, Zhang, Tao, PhD, Yang, Qing, MD, Zou, Jianjun, MD

Get full text